🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "significant breakthrough" in the battle against superbug strains of the pathogen, according to researchers.

A Worldwide Health Concern

Cases of gonorrhoea are increasing worldwide, with estimates suggesting over 82 million infections per year. Particularly high rates are observed in Africa and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an important and timely step in the context of rising global incidence, increasing antimicrobial resistance and the very limited therapeutic options at this time.”

Medical experts are deeply concerned about the surge in antibiotic-resistant strains. The WHO has classified it as a "high-priority threat". Ongoing monitoring showed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Gain Clearance

One new antibiotic, also known as a brand name, was cleared by the American regulatory agency in mid-December for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help delay the development of resistance.

Another new antibiotic, developed by the drugmaker GSK, gained clearance in concurrent days. This treatment, which is also used to treat UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This authorization signifies a huge turning point in the therapy of highly resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Research Study Results and Worldwide Availability

According to findings released by a major medical journal, zoliflodacin successfully treated the vast majority of uncomplicated infections. This places it at an equal footing with the current standard treatment, which uses two antibiotics. The trial involved nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the authority to license and sell the drug in a wide range of developing nations.

Doctors on the front lines have shared hope. The availability of a easy-to-administer therapy such as this is seen as a "critical tool" for public health efforts. This is considered crucial to alleviate the strain of the illness for patients and to prevent the spread of extremely resistant gonorrhoea worldwide.